These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 38459552

  • 1. Effects of depot medroxyprogesterone acetate, the copper IUD and the levonorgestrel implant on testosterone, sex hormone binding globulin and free testosterone levels: ancillary study of the ECHO randomized clinical trial.
    Hofmeyr GJ, Singata-Madliki M, Batting J, Balakrishna Y, Morroni C.
    BMC Womens Health; 2024 Mar 08; 24(1):167. PubMed ID: 38459552
    [Abstract] [Full Text] [Related]

  • 2. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.
    Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium.
    Lancet; 2019 Jul 27; 394(10195):303-313. PubMed ID: 31204114
    [Abstract] [Full Text] [Related]

  • 3. Effects of Depot Medroxyprogesterone Acetate Intramuscular Injection, Copper Intrauterine Device and Levonorgestrel Implant Contraception on Estradiol Levels: An Ancillary Study of the ECHO Randomized Trial.
    Ryan R, Mussa A, Singtaa-Madliki M, Batting J, Balakrishna Y, Morroni C, Hofmeyr GJ.
    Front Glob Womens Health; 2022 Jul 27; 3():887541. PubMed ID: 35669313
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Behavioral effects of different contraceptive methods and HIV acquisition: an ancillary study of the ECHO randomized trial.
    Singata-Madliki M, Lawrie TA, Balakrishna Y, d'Hellencourt FC, Hofmeyr GJ.
    Reprod Health; 2021 Sep 29; 18(1):192. PubMed ID: 34587971
    [Abstract] [Full Text] [Related]

  • 6. Effects of Depot Medroxyprogesterone Acetate, Copper Intrauterine Devices, and Levonorgestrel Implants on Early HIV Disease Progression.
    Morrison CS, Hofmeyr GJ, Thomas KK, Rees H, Philip N, Palanee-Phillips T, Nanda K, Nair G, Onono M, Mastro TD, Lind M, Heffron R, Edward V, Deese J, Beksinska M, Beesham I, Stringer JSA, Baeten JM, Ahmed K, ECHO Trial Team.
    AIDS Res Hum Retroviruses; 2020 Aug 29; 36(8):632-640. PubMed ID: 32394723
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Weight change among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Findings from a randomised, multicentre, open-label trial.
    Beksinska M, Issema R, Beesham I, Lalbahadur T, Thomas K, Morrison C, Hofmeyr GJ, Steyn PS, Mugo N, Palanee-Phillips T, Ahmed K, Nair G, Baeten JM, Smit J.
    EClinicalMedicine; 2021 Apr 29; 34():100800. PubMed ID: 33898953
    [Abstract] [Full Text] [Related]

  • 9. Incidence of Herpes Simplex Virus Type 2 Infection Among African Women Using Depot Medroxyprogesterone Acetate, a Copper Intrauterine Device, or a Levonorgestrel Implant for Contraception: A Nested Randomized Trial.
    Mugo NR, Stalter RM, Heffron R, Rees H, Scoville CW, Morrison C, Kourtis AP, Bukusi E, Beksinka M, Philip NM, Beesham I, Deese J, Edward V, Donnell D, Baeten JM, Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium.
    Clin Infect Dis; 2022 Sep 10; 75(4):586-595. PubMed ID: 34910143
    [Abstract] [Full Text] [Related]

  • 10. Weight variation in users of depot-medroxyprogesterone acetate, the levonorgestrel-releasing intrauterine system and a copper intrauterine device for up to ten years of use.
    Modesto W, de Nazaré Silva dos Santos P, Correia VM, Borges L, Bahamondes L.
    Eur J Contracept Reprod Health Care; 2015 Feb 10; 20(1):57-63. PubMed ID: 25160484
    [Abstract] [Full Text] [Related]

  • 11. The Effect of Contraception on Genital Cytokines in Women Randomized to Copper Intrauterine Device, Depot Medroxyprogesterone Acetate, or Levonorgestrel Implant.
    Tanko RF, Bunjun R, Dabee S, Jaumdally SZ, Onono M, Nair G, Palanee-Phillips T, Harryparsad R, Happel AU, Gamieldien H, Qumbelo Y, Sinkala M, Scoville CW, Heller K, Baeten JM, Bosinger SE, Burgener A, Heffron R, Jaspan HB, Passmore JAS.
    J Infect Dis; 2022 Sep 13; 226(5):907-919. PubMed ID: 35263421
    [Abstract] [Full Text] [Related]

  • 12. Weight change at 12 months in users of three progestin-only contraceptive methods.
    Vickery Z, Madden T, Zhao Q, Secura GM, Allsworth JE, Peipert JF.
    Contraception; 2013 Oct 13; 88(4):503-8. PubMed ID: 23582238
    [Abstract] [Full Text] [Related]

  • 13. Post-randomization Differences in Condomless Vaginal Sex Among Women Randomized to Intramuscular Depot Medroxyprogesterone Acetate Injections, a Copper Intrauterine Device or a Levonorgestrel Implant in the ECHO Trial.
    Deese J, Chen PL, Gao X, Heffron R, Hobbs M, Lapple D, Jaspan H, Miller A, Nair G, Onono M, Palanee-Phillips T, Reddy K, Steiner MJ.
    AIDS Behav; 2023 Mar 13; 27(3):978-983. PubMed ID: 36357806
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The injectable contraceptives depot medroxyprogesterone acetate and norethisterone enanthate substantially and differentially decrease testosterone and sex hormone binding globulin levels: A secondary study from the WHICH randomized clinical trial.
    Avenant C, Singata-Madliki M, Bick AJ, Africander D, Balakrishna Y, Storbeck KH, Moliki JM, Dlamini S, Skosana S, Smit J, Beksinska M, Beesham I, Seocharan I, Batting J, Hofmeyr GJ, Hapgood JP.
    PLoS One; 2024 Mar 13; 19(8):e0307736. PubMed ID: 39178280
    [Abstract] [Full Text] [Related]

  • 17. Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion.
    Steinauer JE, Upadhyay UD, Sokoloff A, Harper CC, Diedrich JT, Drey EA.
    Contraception; 2015 Dec 13; 92(6):553-9. PubMed ID: 26093190
    [Abstract] [Full Text] [Related]

  • 18. Sexually transmitted infections among women randomised to depot medroxyprogesterone acetate, a copper intrauterine device or a levonorgestrel implant.
    Deese J, Philip N, Lind M, Ahmed K, Batting J, Beksinska M, Edward VA, Louw CE, Onono M, Palanee-Phillips T, Smit JA, Baeten JM, Donnell D, Mastro TD, Mugo NR, Nanda K, Rees H, Morrison C.
    Sex Transm Infect; 2021 Jun 13; 97(4):249-255. PubMed ID: 33208512
    [Abstract] [Full Text] [Related]

  • 19. Safety and continued use of the levonorgestrel intrauterine system as compared with the copper intrauterine device among women living with HIV in South Africa: A randomized controlled trial.
    Todd CS, Jones HE, Langwenya N, Hoover DR, Chen PL, Petro G, Myer L.
    PLoS Med; 2020 May 13; 17(5):e1003110. PubMed ID: 32442189
    [Abstract] [Full Text] [Related]

  • 20. Effect of low-dose oral contraceptives on androgenic markers and acne.
    Thorneycroft IH, Stanczyk FZ, Bradshaw KD, Ballagh SA, Nichols M, Weber ME.
    Contraception; 1999 Nov 13; 60(5):255-62. PubMed ID: 10717776
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.